U.S. Government Tells High Court To Hear Fight Over ‘Skinny Label’ Infringement
WASHINGTON, D.C. — In an amicus curiae brief, the U.S. government tells the U.S. Supreme Court that it should take up a bioequivalent drug manufacturer’s petition for a writ of certiorari...To view the full article, register now.
Already a subscriber? Click here to view full article